Experienced in IgG4-Related Disease

Dr. Mark G. Goldstein

Hematology Oncology | Oncology | Hematology
American Oncology Partners PA
6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
Accepting New Patients
Offers Telehealth

Experienced in IgG4-Related Disease
American Oncology Partners PA
6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Goldstein is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Goldstein is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Childhood Iron Deficiency Anemia, Anal Cancer, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma. Dr. Goldstein is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of IgG4-Related Disease.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in CT
Hospital Affiliations
Frederick Health Hospital
Suburban Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

AMERICAN ONCOLOGY PARTNERS PA
6410 Rockledge Dr, Suite 660, Bethesda, MD 20817
Call: 301-571-0019
Other Locations
AMERICAN ONCOLOGY PARTNERS PA
106 Irving St Nw, Suite 4100, Washington, DC 20010
Call: 202-726-0941

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
View 6 Less Clinical Trials

3 Total Publications

IgG4-related Disease Presenting as a Pancreatic Mass and Bilateral Lacrimal Gland Swelling.
IgG4-related Disease Presenting as a Pancreatic Mass and Bilateral Lacrimal Gland Swelling.
Journal: Cureus
Published: April 04, 2017
View All 3 Publications
Similar Doctors
Advanced in IgG4-Related Disease
Dr. Elliot M. Epner
Hematology Oncology | Hematology | Oncology
Advanced in IgG4-Related Disease
Dr. Elliot M. Epner
Hematology Oncology | Hematology | Oncology

Sinai Hospital Of Baltimore, Inc

2401 E Belvedere Ave, 
Baltimore, MD 
 (32.8 miles away)
410-601-4608
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Elliot Epner is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Epner is rated as an Advanced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Mantle Cell Lymphoma (MCL), Breast Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Epner is currently accepting new patients.

Experienced in IgG4-Related Disease
Dr. Peter R. Graze
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Peter R. Graze
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

10710 Charter Dr, Suite G020, 
Columbia, MD 
 (18.8 miles away)
410-964-2218
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Graze is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Graze is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Graze is currently accepting new patients.

Experienced in IgG4-Related Disease
Dr. Adam J. Goldrich
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Adam J. Goldrich
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

6420 Rockledge Dr, Suite 4200, 
Bethesda, MD 
 (0.1 miles away)
301-929-0765
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Goldrich is a Hematologist Oncology specialist and a Hematologist in Bethesda, Maryland. Dr. Goldrich is rated as an Advanced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Multiple Myeloma. Dr. Goldrich is currently accepting new patients.

VIEW MORE IGG4-RELATED DISEASE DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldstein's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Goldstein is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Childhood Iron Deficiency Anemia
      Dr. Goldstein is
      Distinguished
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Myelodysplastic Syndrome (MDS)
      Dr. Goldstein is
      Distinguished
      . Learn about Myelodysplastic Syndrome (MDS).
      See more Myelodysplastic Syndrome (MDS) experts
    • Pleuropulmonary Blastoma
      Dr. Goldstein is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Advanced
    • Astrocytoma
      Dr. Goldstein is
      Advanced
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Goldstein is
      Advanced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Brain Tumor
      Dr. Goldstein is
      Advanced
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    • Dehydration
      Dr. Goldstein is
      Advanced
      . Learn about Dehydration.
      See more Dehydration experts
    • Drug-Induced Thrombocytopenia
      Dr. Goldstein is
      Advanced
      . Learn about Drug-Induced Thrombocytopenia.
      See more Drug-Induced Thrombocytopenia experts
    • Embryonal Tumor with Multilayered Rosettes
      Dr. Goldstein is
      Advanced
      . Learn about Embryonal Tumor with Multilayered Rosettes.
      See more Embryonal Tumor with Multilayered Rosettes experts
    View All 26 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Goldstein is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acquired Agranulocytosis
      Dr. Goldstein is
      Experienced
      . Learn about Acquired Agranulocytosis.
      See more Acquired Agranulocytosis experts
    • Acute Eosinophilic Pneumonia
      Dr. Goldstein is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Mountain Sickness
      Dr. Goldstein is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Goldstein is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Goldstein is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    View All 128 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved